GS 0174
Alternative Names: FSI-174; GS-0174Latest Information Update: 07 Nov 2022
At a glance
- Originator Forty Seven
- Developer Gilead Sciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Macrophage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 07 Nov 2022 Discontinued - Phase-I for Haematological malignancies in USA (Parenteral) (Gilead Sciences pipeline, November 2022)
- 18 Feb 2021 Phase-I clinical trials in Haematological malignancies in USA (Parenteral) (Gilead Science pipeline, February 2021)
- 07 Apr 2020 Gilead Sciences completes acquisition of Forty Seven